NCT07022366View on ClinicalTrials.gov

Investigating the Neuropsychological Effects of 5-HT2a Antagonism

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Healthy
Interventions
DRUG

Pimavanserin 10mg

Single dose of pimavanserin (10mg)

DRUG

Placebo

Sucrose tablet

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, University of Oxford, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER